Inadequacies in current therapies for atrial fibrillation have made new drug development
crucial. Conventional antiarrhythmic drugs increase the risk of ventricular proarrhythmia. In …

Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical
practice. However, current therapeutic interventions for atrial fibrillation have limited clinical …

Background: Different antihypertensive drug classes may alter risk for atrial fibrillation. Some
studies suggest that drugs that interfere with the renin–angiotensin system may be favorable …

In the light of the progressively increasing prevalence of atrial fibrillation (AF), medical
awareness of the need to develop improved therapeutic approaches for the arrhythmia has …

BACKGROUND: We previously showed that omega-3 polyunsaturated fatty acids (PUFAs)
reduce vulnerability to atrial fibrillation (AF). The mechanisms underlying this effect are …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in clinical practice, and there is an increasing trend in its prevalence in the general …

The therapy or prevention of atrial fibrillation (AF) is defined as upstream therapy when
conducted with the use of drugs, eg, angiotensin-converting enzyme inhibitors (ACEIs) …

Background Catheter ablation is an established therapy for atrial fibrillation but is limited by
recurrence; efforts have been made to identify biomarkers that predict recurrence. We …

Coronary revascularization with conventional CABG has the best evidence for improving
outcome in patients with ischemic heart disease. Three main complications after CABG are …

BACKGROUND: Atrial fibrillation (AF) continues to be one of the most common cardiac
problems, placing an expanding burden on the public health system. In several …